On May 29, 2025, D. Boral Capital, with analyst Jason Kolbert, reiterated its 'Buy' rating for Anixa Biosciences (ANIX, Financial). The firm maintained the price target at $10.00 USD.
This decision reflects consistency in their outlook for ANIX, as the adjusted price target remains unchanged from the prior assessment, indicating continued confidence in the company's performance.
Investors looking to track Anixa Biosciences (ANIX, Financial) may find this reaffirmed rating and stable price target insightful as they consider their investment strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Anixa Biosciences Inc (ANIX, Financial) is $9.00 with a high estimate of $10.00 and a low estimate of $7.00. The average target implies an upside of 254.33% from the current price of $2.54. More detailed estimate data can be found on the Anixa Biosciences Inc (ANIX) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Anixa Biosciences Inc's (ANIX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
